期刊文献+

喷他脒增强K562细胞对肿瘤坏死因子相关凋亡诱导配体诱导凋亡敏感性 被引量:1

Pentamidine sensitizes leukemia K562 cells to TRAIL-induced apoptosis
下载PDF
导出
摘要 背景与目的:肿瘤坏死因子相关凋亡诱导配体(TRAIL)是一种理想的抗肿瘤药物,但许多肿瘤细胞常对TRAIL诱导凋亡耐受。本研究探讨了喷他脒增强白血病K562细胞对TRAIL诱导凋亡敏感性。方法:利用光镜形态学和AnnexinVFITC/PI双标记凋亡细胞的流式细胞仪(FACS)测定两种方法观察喷他脒预处理K562细胞并继用TRAIL后凋亡的发生。应用蛋白印迹方法观察此过程中半胱氨酸-天冬氨酸蛋白酶(Caspase)-3,-8和聚ADP核糖聚合酶(PARP)等3种蛋白的蛋白剪切与X连锁凋亡抑制蛋白(XIAP)蛋白表达的改变。结果:在10μg/ml喷他脒作用K562细胞20h,K562细胞未发生凋亡,继用200ng/mlTRAIL作用4h后,光镜和AnnexinVFITC/PI双标记流式细胞仪方法均观察到细胞发生明显凋亡,并出现了Caspase-3,-8和PARP蛋白剪切,两者单独作用则无明显细胞凋亡发生。另外,喷他脒明显降低了XIAP表达。结论:喷他脒联合TRAIL可能成为肿瘤治疗的一种新策略。 Background and purpose: Tumor necrosis factor-related apoptosis inducing ligand (TRA1L) is a success- ful clinical anti-tumor agent, ttowever, not all tumor cells are sensitive to TRAIL-mediated apoptosis. In this study, we examined the TRAIL-induced apoptosis after pretreatment with pentanddine in K562 cells. Methods: When K562 ceils were pretreated with pentamidine followed by TRAIL, apoptosis of fells was analyzed by cellular morphology via viewing live ceils under a light micrnscope and annexin V-FlTC/propidium iodine FACS. Western blot was perfbrmed t. examine the cleavage of caspase-3,-8 and poly(ADP-ribose) polymerase (PARR) attd protein levels of X-linked inhibitor of apoptosis protein ( XIAP). Results: Apoptotic cell death occurred and cleavage of caspase-3, -8 and PARR appeared when K562 cells were pretreated with 10μg/ml of pentamidine followed hy 200 ng/rnl of TRAIL, In addition, penlamidine decreased protein levels of X1AP. Conclusions: Combined treatment with penlamidine and TRAIL may become a new slrategy for cancer lherapy
出处 《中国癌症杂志》 CAS CSCD 2007年第12期951-954,共4页 China Oncology
关键词 喷他眯 肿瘤坏死因子相关凋亡诱导配体 肿瘤 pentamidine: TRAIL, tumor
  • 相关文献

参考文献13

  • 1Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis[J]. Immunity,1995,3(6) :673-682.
  • 2Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo [J]. Nat Med,1999,5(2) :157-163.
  • 3Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL[J]. Curr Opin Pharmacol,2004,4(4) :333-339.
  • 4Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications [ J ]. Blood, 2001,98 (3) :795-804.
  • 5Younes A, Aggarwall BB. Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders [ J ]. Cancer,2003,98 ( 3 ) :458-467.
  • 6Shankar S, Srivastava RK. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications [ J ]. Drug Resist Updat, 2004,7 ( 2 ) : 139-156.
  • 7Pathak MK, Dhawan D, Lindner D J, et al. Pentamidine is an inhibitor of PRL phosphatases with anticancer activity [ J ]. Mol Cancer Ther,2002,1 (14) : 1255-1264.
  • 8Kim KM, Song JJ, An JY, et al. Pretreatment of acetylsalicylic acid promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by down-regulating BCL-2 gene expression [J]. J Biol Chem,2005,280(49) :41047.4156.
  • 9Di Pietro R, Secchiero P, Rana R, et al. Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) :mediated cytotoxicity by selective up-regulation of TRAIL-R1 [ J ]. Blood ,2001,97 ( 9 ) :2596-2603.
  • 10Bronner U, Doua F, Ericsson O, et al. Pentamidine concentrations in plasma, whole blood and cerebrospinal fluid during treatment of Trypanosoma gambiense infection in Cote d' Ivoire [ J ]. Trans R Soc Trop Med Hyg,1991,85(5) :608-611.

同被引文献10

  • 1Barrett SV, Barrett MP. Anti-sleeping sickness drugs and cancer c- hemotherapy [ J ]. Parasitol Today,2006,1 (16) :7-9.
  • 2Coelho AC, Messier N, Ouellette M, et al. Role of the ABC trans- porter PRP1 (ABCC7) in pentamidine resistance in leishmania amastigotes [ J ]. Antimicrob Agents Chemother, 2007,51 ( 8 ) : 3030-3032.
  • 3Helweg-Larsen J, Benfield T, Atzori C, et al. Clinical efficacy of first- and second-line treatments for HIV-associated pneumocystis jirovecii pneumonia: a tri-centre cohort study [ J]. J Antimicrob Chemother,2009,64 (6) : 1282-1290.
  • 4Watanabe M, Aoki Y, Kurata H, et al. Pneumocystis carinii pneu- monia in a patient with stage IV ovsrian cancer [ J ]. Gynecol On- col ,2002,11 ( 87 ) :225-227.
  • 5Nordenberg J, Fenig E, Landau M, et al. Effects of psycho-tropic drugs on cell proliferation and differentiation [ J ]. Biochem Phar- macol, 1999,58 ( 8 ) :221-229.
  • 6Chow TY, Alaoui-Jamali MA, Yeh C, et al. The DNA double-stran- ded break repair protein endo-exonuclease as a therapeutic target for cancer [ J ]. Mol Cancer Ther,2004,8 (3) :911-919.
  • 7Smith J, Stewart B J, Glaysher S, et al. The effect of pentamidine on melanoma ex vivo[ J]. Anticancer Drugs,2010,21 (2) :181-185.
  • 8Pathak MK, Dhawan D, Lindner DJ, et al. Pentanz line is an inhibi-tor of PRL phosphatases with anticancer activiIMol CancerTher,2002,1 (14) :1255-1264.
  • 9Jarak I, MarjanoviO M, Piantanida I, et al. Novel pentamidine deriv- atives : synthesis, anti-tumor properties and polynucleotide-binding activities[ J]. Eur J Med Chem,2011,46(7 ) :2807-2815.
  • 10李月红,易建平,王晓燕.喷他脒对人宫颈癌细胞株Hela细胞增殖和诱导凋亡的作用[J].军医进修学院学报,2008,29(2):95-97. 被引量:2

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部